Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Blood (2024) 144 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2024-199336

Published: 2024

Journal Articles

MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2

Mark J Althoff, Mohd Minhajuddin, Brett M Stevens, Austin E Gillen, Regan Miller, Ana Vujovic, Sweta B Patel, William Showers, Stephanie Gipson, Monika Dzieciatkowska, Jana M Ellegast, Tristen Wright, Kimberly Stegmaier, Joseph T Opferman, Craig T Jordan

Blood (2024) 144 (Supplement 1): 39.

https://doi.org/10.1182/blood-2024-206516

Published: 2024

Journal Articles

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan Gutman, Andrew Kent, Diana Abbott, Connor Sohalski, Jessica Dell-Martin, Ayele Belachew, Brett M Stevens, Craig T Jordan, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2024-202839

Published: 2024

Journal Articles

CD64 CAR-T Therapy Targets Venetoclax-Resistant Monocytic Acute Myeloid Leukemia

Haley M. Simpson, Amanda Novak, Catherine Danis, Michael Yarnell, Phoebe Duong, Brett M Stevens, Craig T Jordan, M. Eric Kohler

Blood (2024) 144 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2024-205683

Published: 2024

Journal Articles

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan A Gutman, Connor Sohalski, Jennifer Tobin, Austin E Gillen, Anagha Inguva Sheth, Brett M Stevens, Clayton Smith, Craig T. Jordan, Daniel A. Pollyea

Blood (2023) 142 (Supplement 1): 2914.

https://doi.org/10.1182/blood-2023-182966

Published: 2023

Journal Articles

Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells

Blood (2023) 142 (Supplement 1): 588.

https://doi.org/10.1182/blood-2023-188285

Published: 2023

Journal Articles

A Novel CD64 CAR-T Therapy for the Treatment of Monocytic Acute Myeloid Leukemia

Haley M. Simpson, Brett M Stevens, Craig T. Jordan, M. Eric Kohler

Blood (2023) 142 (Supplement 1): 2064.

https://doi.org/10.1182/blood-2023-182123

Published: 2023

Journal Articles

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Blood (2022) 140 (Supplement 1): 3275–3276.

https://doi.org/10.1182/blood-2022-157802

Published: 2022

Journal Articles

Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens

Mohd Minhajuddin, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Nicholas Miltgen, Ji Yuan, Amy Treece, Jonathan A. Gutman, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6274–6275.

https://doi.org/10.1182/blood-2022-167856

Published: 2022

Journal Articles

Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Anagha Inguva, Krysta L. Engel, Hunter Tolison, Mark J Althoff, Shanshan Pei, Maria L. Amaya, Anna Krug, Mohammad Minhajuddin, Courtney L Jones, Austin E. Gillen, Monica Ransom, Sarah Staggs, Daniel A. Pollyea, Clayton Smith, Brett M. Stevens, Craig T. Jordan

Blood (2022) 140 (Supplement 1): 5922–5923.

https://doi.org/10.1182/blood-2022-167787

Published: 2022

Journal Articles

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Christine M. McMahon, Kellen Gil, Maria L. Amaya, Jonathan A. Gutman, Alexander Hayden, Marc Schwartz, Grace Bosma, Diana Abbott, Brett M. Stevens, Clayton Smith, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6185–6186.

https://doi.org/10.1182/blood-2022-170168

Published: 2022

Journal Articles

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Alexander Hayden, Grace Bosma, Jonathan A. Gutman, Maria L. Amaya, Diana Abbott, Clayton Smith, Brett M. Stevens, Craig T. Jordan, Daniel A. Pollyea, Christine M. McMahon

Blood (2022) 140 (Supplement 1): 9163–9164.

https://doi.org/10.1182/blood-2022-171064

Published: 2022

Journal Articles

Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies

Brett M. Stevens, Amanda C. Winters, Mohammad Minhajuddin, Maria L. Amaya, Christine M. McMahon, Jonathan A. Gutman, Clayton Smith, Deng Wang, Connor Adkins, Olivia Ondracek, Craig T. Jordan, Daniel A. Pollyea

Blood (2021) 138 (Supplement 1): 2612.

https://doi.org/10.1182/blood-2021-150824

Published: 2021

Journal Articles

Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Mohd Minhajuddin, Haobin Ye, Amanda C. Winters, Shanshan Pei, Nabilah Khan, Brett M. Stevens, Biniam Adane, Maria L. Amaya, Anagha Inguva, Anna Krug, Maura Gasparetto, Daniel W. Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T. Jordan

Blood (2021) 138 (Supplement 1): 630.

https://doi.org/10.1182/blood-2021-151400

Published: 2021

Journal Articles

Prolonged Omacetaxine Treatment Alters Fitness and Proteostasis in Multiple Myeloma

Zachary J Walker, Rachel N Steinmetz, Denis J Ohlstrom, Lauren T Reiman, Taylor S Mills, Beau M Idler, Brett M. Stevens, Eric Pietras, Daniel W. Sherbenou

Blood (2021) 138 (Supplement 1): 1604.

https://doi.org/10.1182/blood-2021-151953

Published: 2021

Journal Articles

Unique Metabolic Vulnerabilities of Myelodysplastic Syndrome Stem Cells

Brett M. Stevens, Krysta L. Engel, Austin E. Gillen, Rachel Culp-Hill, Angelo Dalessandro, Scott Alper, Daniel A. Pollyea, Craig T. Jordan

Blood (2021) 138 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2021-150749

Published: 2021

Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-136120

Published: 2020

Journal Articles

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

Courtney L Jones, PhD, Brett M. Stevens, PhD, Rachel Culp-Hill, BS, Angelo Dalessandro, PhD, Anna Krug, BS, Madeline Goosman, Shanshan Pei, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD

Blood (2019) 134 (Supplement_1): 1272.

https://doi.org/10.1182/blood-2019-125773

Published: 2019

Journal Articles

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

James Chavez, BS, Jennifer L Rabe, BS, BA, Kelly Higa, MS, Dirk Loeffler, Ahmed Nouraiz, PhD, Taylor Mills, BA, Beau M Idler, Brett M. Stevens, PhD, Courtney Fleenor, PhD, Claus Nerlov, PhD, Hideaki Nakajima, MD, James Hagman, Timm Schroeder, PhD, Hyun Min Kim, PhD, Craig T Jordan, PhD, James DeGregori, Eric Pietras, PhD

Blood (2019) 134 (Supplement_1): 822.

https://doi.org/10.1182/blood-2019-129300

Published: 2019

Journal Articles

Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes

Marlie H Fisher, Greg Kirkpatrick, PhD, Courtney L Jones, PhD, Brett M. Stevens, PhD, Michael Callaghan, MD, Eric Pietras, PhD, Kenneth L. Jones, PhD, Christopher C. Porter, MD, Jorge Di Paola, MD

Blood (2019) 134 (Supplement_1): 2316.

https://doi.org/10.1182/blood-2019-132032

Published: 2019

NARROW

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

CD64 CAR-T Therapy Targets Venetoclax-Resistant Monocytic Acute Myeloid Leukemia

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells

A Novel CD64 CAR-T Therapy for the Treatment of Monocytic Acute Myeloid Leukemia

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens

Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies

Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Prolonged Omacetaxine Treatment Alters Fitness and Proteostasis in Multiple Myeloma

Unique Metabolic Vulnerabilities of Myelodysplastic Syndrome Stem Cells

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation

Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only